MARATTO

article · Future Medicinal Chemistry

Design and synthesis of novel 3,5-diphenyl pyrazolines acting as potent EGFR inhibitors with off-target antileukemic effect

2025Open accessSinai University

Abstract

AIM: bearing the terminal piperidine or morpholine moieties commonly observed in clinically approved EGFR inhibitors were synthesized as novel anti-cancer agents acting via EGFR inhibition. MATERIALS & METHODS: anti-cancer activity against 60 NCI cell lines. RESULTS: are expected to be bioavailable and drug-like compounds. CONCLUSION: has off-target antileukemic effect.

Research topics

  • Synthesis and biological activity
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1080/17568919.2025.2559579

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.